Results 251 to 260 of about 5,698,960 (306)
SynergyGraph: predicting cell line specific drug combination synergy scores using knowledge graph representation and hypergraph modeling. [PDF]
Sci RepMehrabani M +5 more
europepmc +1 more source
Identifying Drug Combination Strategies for <i>ZMYM2: FGFR1</i> Fusion Positive Leukemia. [PDF]
Precis OncogenomHuang A +6 more
europepmc +1 more source
Condensation of fluconazole and zinc undecylanate particles using low-pressure RF plasma: a novel drug combination approach. [PDF]
BMC Pharmacol ToxicolBilici N, Bozduman F.
europepmc +1 more source
VCTatDot and VCTatMLP: novel deep learning models with triadic attention embeddings for synergistic drug combination prediction. [PDF]
Sci RepMajidifar S, Hooshmand M.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of the American Medical Directors Association, 2005
Caring for the elderly nursing home patient has never been more clinically complex or administratively more troublesome. Patients carry with them a greater burden of disease with increasing frailty and vulnerability. More drugs are being used for more problems.
Eric G, Tangalos, Barbara J, Zarowitz
openaire +2 more sources
Caring for the elderly nursing home patient has never been more clinically complex or administratively more troublesome. Patients carry with them a greater burden of disease with increasing frailty and vulnerability. More drugs are being used for more problems.
Eric G, Tangalos, Barbara J, Zarowitz
openaire +2 more sources
Multiple Sclerosis Journal, 1996
As a result of recent therapeutic trials, recombinant Interferon beta (r/FNβ)-1b and-1a as well as Copolymer 1 (COP 1) and to some extent unspecific immunosuppressants have been accepted as partially efficient treatments of relapsing-remitting MS. In view of partially effective single treatments, the question arises if combination of two or even more ...
openaire +3 more sources
As a result of recent therapeutic trials, recombinant Interferon beta (r/FNβ)-1b and-1a as well as Copolymer 1 (COP 1) and to some extent unspecific immunosuppressants have been accepted as partially efficient treatments of relapsing-remitting MS. In view of partially effective single treatments, the question arises if combination of two or even more ...
openaire +3 more sources
2013
Antimicrobial combination therapy has a long history. The potential for synergy between two antimicrobial agents has been sought using in vitro techniques such as disk approximation, checkerboard titration, in vitro killing experiments with fixed drug concentrations, through the use of in vitro pharmacodynamic models, through animal models, and through
openaire +1 more source
Antimicrobial combination therapy has a long history. The potential for synergy between two antimicrobial agents has been sought using in vitro techniques such as disk approximation, checkerboard titration, in vitro killing experiments with fixed drug concentrations, through the use of in vitro pharmacodynamic models, through animal models, and through
openaire +1 more source
Rationale for drug combinations
European Journal of Cancer, 2003No reader of this journal needs to be reminded that real progress in the treatment of solid tumours is hard to achieve. The explosion of scientific knowledge about the metabolism of tumours and the genetic influences that promote or restrict growth will it is hoped lead to the more rationale design of therapeutics, which in future will be more ...
openaire +2 more sources